Search Result

Results for "

intervention

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CCR (2) Endogenous Metabolite (2) Epigenetic Reader Domain (1) Fungal (1) Isotope-Labeled Compounds (1) Melanocortin Receptor (1) SARS-CoV (2) Thrombin (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (1) Metabolic Disease (3) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W015399

4-Methylcinnamic acid	Fungal	Infection
4-Methylcinnamic acid, a Cinnamic acid analog, can be used as a intervention catalyst for overcoming antifungal tolerance. 4-Methylcinnamic acid can improve the potency of cell wall-disrupting agents .

HY-P1929

Bivalirudin 5+ Cited Publications	Thrombin	Cardiovascular Disease
Bivalirudin, a peptide anticoagulant, is a direct thrombin inhibitor for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary intervention .

HY-N0610A

Cinnamic acid 3-Phenylacrylic acid; β-Phenylacrylic acid
Cinnamic acid has potential use in cancer intervention, with IC₅₀s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.

HY-B2165

Bendazac L-Lysine	Others	Others
Bendazac L-Lysine is one of agents that have been introduced for the management of cataracts, protecting the level of vision in patients, thus delaying the need for surgical intervention.

HY-N0610AS

Cinnamic acid-d6 3-Phenylacrylic acid-d₆; β-Phenylacrylic acid-d₆	Endogenous Metabolite	Cancer
Cinnamic acid-d₆ is the deuterium labeled Cinnamic acid. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.

HY-N6077

Thalidezine	Others	Cancer
Thalidezine is a novel activator of AMP-activated protein kinase (AMPK). Thalidezine can eliminate anti-apoptotic cancer cells through energy-mediated autophagy death. Thalidezine can be used to study apoptosis intervention .

HY-B1657

Fosphenytoin	Others	Neurological Disease
Fosphenytoin is a phosphate ester proagent developed as an alternative to intravenous phenytoin for acute intervention of seizures. Fosphenytoin has advantages including more convenient and rapid intravenous administration, availability for intramuscular injection, and low potential for adverse local reactions at injection sites .

HY-116572A

TASIN-1	Others	Cancer
TASIN-1 is a selective inhibitor of truncated *APC* gene (adenomatous polyposis coli gene) and exerts cytotoxic effects through inhibition of cholesterol biosynthesis. TASIN-1 represents a potential therapeutic strategy for prevention and intervention in CRC with mutant APC .

HY-N0610AS2

Cinnamic acid-13C3 3-Phenylacrylic acid-¹³C₃; β-Phenylacrylic acid-¹³C₃	Isotope-Labeled Compounds Endogenous Metabolite	Cancer
Cinnamic acid- ¹³C₃ (3-Phenylacrylic acid- ¹³C₃) is the ¹³C labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC₅₀s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells .

HY-N6901

Luteolin 7-sulfate	Epigenetic Reader Domain	Metabolic Disease
Luteolin 7-sulfate is isolated from Phyllospadix iwatensis Makino, a marine plant. Luteolin 7-sulfate attenuates TYR gene expression through the intervention of a cAMP-responsive element binding protein (CREB)- and microphthalmia-associated transcription factor (MITF)-mediated signaling pathway, leading to the decreased melanin synthesis .

HY-P99004

hMC1R agonist 1	Melanocortin Receptor	Inflammation/Immunology
(EC₅₀=3 nM). hMC1R agonist 1 shows at least 300-fold selectivity for hMC1R over hMC3R (b>EC₅₀=902 nM), hMC4R (b>EC₅₀=915 nM), and hMC5R (b>EC₅₀=>1000 nM). hMC1R agonist 1 has the potential for the therapeutic intervention of melanocortin family .

HY-145276

SARS-CoV-2-IN-10	SARS-CoV	Infection
SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC₅₀ and EC₅₀ of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .

HY-145277

SARS-CoV-2-IN-11	SARS-CoV	Infection
SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC₅₀ and EC₅₀ of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .

HY-117621

PF-04634817	CCR	Metabolic Disease
PF-0463481 is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC₅₀=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC₅₀=470 nM). PF-0463481 is safe and well-tolerated and has the potential for the study of diabetic nephropathy .

HY-117621A

PF-04634817 succinate	CCR	Metabolic Disease
PF-0463481 succinate is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC₅₀=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC₅₀=470 nM). PF-0463481 succinate is safe and well-tolerated and has the potential for the study of diabetic nephropathy .

Cat. No.	Product Name

HY-L0106V

Protein-Protein Interaction Modulators Library	2,906 compounds
Protein-protein interactions (PPIs) play a key role in nearly every biological function and are a promising new class of biological targets for therapeutic intervention. This is a collection of 2,906 diverse compounds designed for discovery of PPI modulators.

HY-L064

Glutamine Metabolism Compound Library	903 compounds
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH. Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment. MCE owns a unique collection of 903 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Glutamine Metabolism Compound Library

903 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 903 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

HY-L013

Neuronal Signaling Compound Library	2542 compounds
Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders. MCE designs a unique collection of 2542 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

Neuronal Signaling Compound Library

2542 compounds

Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders.

MCE designs a unique collection of 2542 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

Bivalirudin 5+ Cited Publications	Thrombin	Cardiovascular Disease
Bivalirudin, a peptide anticoagulant, is a direct thrombin inhibitor for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary intervention .

hMC1R agonist 1	Melanocortin Receptor	Inflammation/Immunology
(EC₅₀=3 nM). hMC1R agonist 1 shows at least 300-fold selectivity for hMC1R over hMC3R (b>EC₅₀=902 nM), hMC4R (b>EC₅₀=915 nM), and hMC5R (b>EC₅₀=>1000 nM). hMC1R agonist 1 has the potential for the therapeutic intervention of melanocortin family .

Cat. No.	Product Name	Category	Target	Chemical Structure